Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade

OBJECTIVE: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but come with immune-related adverse events (irAEs) that provide a novel challenge for treating physicians. Neuromuscular irAEs, including myositis, myasthenia gravis (MG), and demyelinating polyradiculoneuropathy, lea...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelke, Christopher, Pawlitzki, Marc, Kerkhoff, Ruth, Schroeter, Christina B., Aktas, Orhan, Neuen-Jacob, Eva, Polzin, Amin, Meuth, Sven G., Ruck, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Clinical/Scientific Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602369/
https://www.ncbi.nlm.nih.gov/pubmed/37884388
http://dx.doi.org/10.1212/NXI.0000000000200177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602369/
https://www.ncbi.nlm.nih.gov/pubmed/37884388
http://dx.doi.org/10.1212/NXI.0000000000200177

Ejemplares similares